We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLDB:NASDAQSolid Biosciences Inc. Analysis

Data as of 2026-09-01 - not real-time

$9.65

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Solid Biosciences Inc. trades at $9.64, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Over a rolling month the price has gained 14.0%. With RSI at 56.2 the momentum picture is neutral, alongside a bullish MACD signal. Watch $8.29 as support and $10.27 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 93.5% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 56.6%, a beta of 2.05 and a maximum drawdown of 38.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 1 out of 10.

Top Market Events

- Duchenne SGT-003 : SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with...Detailed price information for Solid Biosciences Inc SLDB-Q from The Globe and Mail including charting and trades.Yahoo Finance25dSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesThe above...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 7.22
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 7.22
  • Analyst targets imply +93.5% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +93.5% versus the current price
  • Negative return on equity of -65.5%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-5.5
ROE-65.50%
ROA-36.38%
Debt/Equity5.39
P/B Ratio2.7
Op. Cash Flow$-186844000
Free Cash Flow$-118235624
Industry P/E30.6

Technical Analysis

TrendBullish
RSI56.2
Support$8.29
Resistance$10.27
MA 20$9.24
MA 50$9.22
MA 200$7.22
MACDBullish
VolumeStable
Fear & Greed Index94.09

Valuation

Target Price$18.67
Upside/Downside93.54%
GradeFair
TypeBlend

Risk Assessment

Beta2.05
Volatility56.60%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.